Avid Bioservices Inc (CDMO)

[entdoc]

Bavi mechanism of action is now though to be, in part, that of facilitator...that of switching omnipotential and plastic monocyte function from body growth offense to body anti-growth defense. Bavi helps switch monocytes from such tasks as making new blood vessels, newlymphatic channels, and new stroma to that of performing tasks which are pro-host/anti-tumor, by discouraging growth and development of new blood vessels and lymphatic channels and thus discouraging metastases and growth of primary cancer sites. It appears that Bavi's action mirrors that described in FTM's last post re. pancreatic cancer, so perhaps we may reasonably expect significant increased months of survival in that disease, pancreatic cancer. Whether Bavi requires or allows for chronic administration remains a question, but appears to be a possibility. Bavi's role used in combination with surgery, irradiation, and/or chemotherapy seems increasingly promising at this point. It seems clear that in large, established, and aggresive tumors that ablation...whether surgically, chemically, or with irradiation will be necessary in the near-term until earlier cancer detection is possible. And Bavi could conceivably play a role in cancer imaging, moving that goal a step closer to reality. Finally, it seems likely that Bavi will help extend the boundaries of "operability" of certain already advanced tumors and metastases.